PepGen (NASDAQ:PEPG) Stock Bumped Up to Hold by Wall Street Zen

Wall Street Zen upgraded shares of PepGen (NASDAQ:PEPG) from a sell rating to a hold rating in a report issued on Saturday morning,Wall Street Zen reports.

A number of other research analysts have also weighed in on the company. Weiss Ratings raised PepGen from a “sell (e+)” rating to a “sell (d-)” rating in a report on Tuesday, September 22nd. HC Wainwright reiterated a “buy” rating on shares of PepGen in a research report on Wednesday, September 9th. Five research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $11.40.

PepGen Stock Performance

Shares of NASDAQ PEPG opened at $2.47 on Friday. PepGen has a fifty-two week low of $1.31 and a fifty-two week high of $7.80. The stock has a market cap of $171.07 million, a PE ratio of -1.89 and a beta of 2.02. The stock has a fifty day moving average of $2.67 and a 200-day moving average of $3.00.

PepGen (NASDAQ:PEPG) last issued its quarterly earnings data on Thursday, August 6th. The company reported ($0.26) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.28) by $0.02. On average, sell-side analysts predict that PepGen will post -1.11 EPS for the current year.

Institutional Trading of PepGen

A number of hedge funds have recently bought and sold shares of the company. Group One Trading LLC purchased a new stake in PepGen in the first quarter worth approximately $77,000. Seven Fleet Capital Management LP purchased a new position in shares of PepGen during the first quarter worth approximately $105,000. Rangeley Capital LLC raised its stake in shares of PepGen by 88.1% during the first quarter. Rangeley Capital LLC now owns 68,096 shares of the company’s stock worth $121,000 after acquiring an additional 31,896 shares in the last quarter. Persistent Asset Partners Ltd purchased a new position in shares of PepGen during the second quarter worth approximately $171,000. Finally, Connor Clark & Lunn Investment Management Ltd. bought a new stake in shares of PepGen in the 2nd quarter worth approximately $202,000. Institutional investors own 58.01% of the company’s stock.

About PepGen

PepGen Inc is a clinical-stage biotechnology company developing genetic medicines for serious neuromuscular diseases. The company’s technology is designed to improve the delivery of oligonucleotide therapeutics into skeletal and cardiac muscle, with the goal of addressing diseases caused by genetic mutations or abnormal RNA processing.

PepGen’s platform, known as Enhanced Delivery Oligonucleotides (EDO), combines therapeutic oligonucleotides with proprietary peptides intended to facilitate their distribution into muscle tissue.